Protagonist Therapeutics, Inc.

PTGX Healthcare Biotechnology

Protagonist Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, down 89.4% from fiscal 2024. In the quarter to June 2026, revenue grew 3,749.2%, EPS grew 549.1% and free cash flow grew 839.7%, each against the same quarter a year earlier.

128.75 7.80 −5.71%
Market cap
$8.8B
P/E
106×
Fwd P/E
25.0×
Dividend yield
—
F-score
4/9
Altman Z
61.55
Beneish M
−7.18
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
100.48 0.00 0.00 88.57

+8 more quarters

P/S ratio
28.66 92.63 120.66 20.25
P/FCF ratio
61.90 0.00 99.01 66.49
P/Operating CF
36.90 (140.17) (150.17) (2,187.08)
P/B ratio
9.60 10.47 9.03 6.56
EV/Sales
25.92 85.36 108.55 17.54
EV/EBITDA
129.65 0.00 0.00 281.36
EV/FCF
55.98 (53.63) 89.07 57.60
Current Ratio
21.71 17.76 12.71 13.05
Net Debt/EBITDA
(4.96) 143.14 11.13 12.39
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
1.00% (1.71%) (2.35%) 1.13%
Free Cash Flow Yield
1.62% (1.72%) 1.01% 1.50%
Free Cash Flow per Share
3.32 (0.76) (0.58) (0.03)
Book value per Share
12.76 10.07 9.67 10.12
Free Cash Flow
218.88 (49.16) (37.12) (2.02)
EV/EBIT
125.29 0.00 0.00 193.08
Other line items

Show all line items

Columns are period end dates